Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2015-11-18 Investor Presentation
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 18, 2015. It specifically mentions that the management team will be presenting at an Analyst Day event and that the slide presentation is attached as Exhibit 99.1. The content focuses on Regulation FD Disclosure related to the presentation slides for the Analyst Day. There are no financial statements or detailed financial data included in the text, only a reference to the presentation slides. The document is relatively short (3409 characters) and serves to furnish the presentation material rather than being the presentation or report itself. Therefore, this document is best classified as an Investor Presentation (IP).
2015-11-18 English
PRIMARY DOCUMENT
Director's Dealing
2015-11-13 English
PRIMARY DOCUMENT
Director's Dealing
2015-11-13 English
PRIMARY DOCUMENT
Director's Dealing
2015-11-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a lease agreement), termination of a prior lease, and creation of a direct financial obligation. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, call transcript, or governance report. It is a regulatory filing announcing material corporate events and agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is about 5070 characters, which is consistent with a typical 8-K filing. Confidence is high due to clear identification as an 8-K current report with material agreement disclosures.
2015-11-10 English
10-Q
Interim / Quarterly Report Q3 2015
2015-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.